TrialThe oncologist2020

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.

Margaret E Gatti-Mays et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.